A review on colistin nephrotoxicity

European Journal of Clinical Pharmacology

Volumn 71, Issue 7, 2015, Pages 801-810

  Ordooei Javan, Atefeh ^a   Shokouhi, Shervin ^b   Sahraei, Zahra ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adverse effect; Colistin; Incidence; Nephrotoxicity; Risk factor

Indexed keywords

ACETYLCYSTEINE; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ALPHA TOCOPHEROL; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ASTAXANTHIN; COLISTIN; CYSTATIN C; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; MELATONIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROANTHOCYANIDIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

AGE; ANTIOXIDANT ACTIVITY; ATAXIA; BACTERICIDAL ACTIVITY; CONFUSION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG MEGADOSE; DYSPHAGIA; HALLUCINATION; HUMAN; HYPERBILIRUBINEMIA; HYPOALBUMINEMIA; KIDNEY INJURY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OLIGURIA; OPHTHALMOPLEGIA; PARESTHESIA; PARTIAL HEARING LOSS; POLYPHARMACY; PRIORITY JOURNAL; PROTEINURIA; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SEIZURE; SEX DIFFERENCE; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; VERTIGO; VISUAL DISORDER; WEAKNESS; ANIMAL; CHEMICALLY INDUCED; DOSE CALCULATION; DRUG ADMINISTRATION; DRUG EFFECTS; INCIDENCE; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; HUMANS; INCIDENCE; KIDNEY; KIDNEY DISEASES; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84930869849     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1865-4     Document Type: Review

References (57)

1. Falagas ME, Kasiakou SK, Saravolatz LD (2005) Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40(9):1333-1341
2. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL (2006) Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6(9):589-601
3. Nation RL, Li J (2009) Colistin in the 21st century. Curr Opin Infect Dis 22(6):535
4. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, Forrest A, Bulitta JB, Tsuji BT (2010) Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacother J Human Pharmacol Drug Ther 30(12):1279-1291
5. John E, Bennett RD, Blaser MJ (2015) Polymyxins (Polymyxin B and Colistin). In: Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 8 edn. Elsevier Saunders, Canada, pp 549-555
6. Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil A (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54(5):670-680
7. Bergen PJ, Li J, Rayner CR, Nation RL (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50(6):1953-1958
8. Mendes CAC, Burdmann EA (2009) Polymyxins: review with emphasis on nephrotoxicity. Rev Assoc Med Bras 55(6):752-759
9. Michalopoulos AS, Falagas ME (2011) Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 1(1):1-6
10. Plachouras D, Karvanen M, Friberg L, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53(8):3430-3436
11. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G (2009) Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 48(12):1724-1728
12. DeRyke CA, Crawford AJ, Uddin N, Wallace MR (2010) Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 54(10):4503-4505
13. Paul M, Bishara J, Levcovich A, Chowers M, Goldberg E, Singer P, Lev S, Leon P, Raskin M, Yahav D (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65(5):1019-1027
14. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, Gregorakos L (2003) Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 7(5):R78
15. Pintado V, San Miguel LG, Grill F, Mejía B, Cobo J, Fortún J, Martín-Dávila P, Moreno S (2008) Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 56(3):185-190
16. Betrosian AP, Frantzeskaki F, Xanthaki A, Douzinas EE (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ∈ventilator-associated pneumonia. J Infect 56(6):432-436
17. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54(12):1720-1726
18. Tuon FF, Rigatto MH, Lopes CK, Kamei LK, Rocha JL, Zavascki AP (2014) Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43(4):349-352
19. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS (2011) Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53(9):879-884
20. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, Raponi G, Vitale M, Pietropaoli P, Antonelli M (2013) Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17:R174
21. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, Álvarez-Lerma F, Knobel H, Benito N, Horcajada JP (2013) Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis 13(1):1-9
22. Kalin G, Alp E, Coskun R, Demiraslan H, Gündogan K, Doganay M (2012) Use of high-dose IV and aerosolized colistin for the treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia: do we really need this treatment? J Infect Chemother 18(6):872-877
23. Duraković N, Radojčić V, Boban A, Mrsić M, Sertić D, Serventi-Seiwerth R, Nemet D, Labar B (2011) Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med (Tokyo, Japan) 50(9):1009-1013
24. Kallel H, Bahloul M, Hergafi L, Akrout M, Ketata W, Chelly H, Hamida CB, Rekik N, Hammami A, Bouaziz M (2006) Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 28(4):366-369
25. Luque S, Grau S, Valle M, Sorlí L, Horcajada JP, Segura C, Álvarez-Lerma F (2013) Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant∈<∈i∈>∈Acinetobacter baumannii Int J Antimicrob Agents 42(2):178-181
26. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M (2010) Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest J 138(6):1333-1339
27. Cheng C-Y, Sheng W-H, Wang J-T, Chen Y-C, Chang S-C (2010) Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 35(3):297-300
28. Roberts JA, Lipman J (2012) Editorial commentary: closing the loop - a colistin clinical study to confirm dosing recommendations from PK/PD modeling. Clin Infect Dis 54(12):1727-1729
29. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25(1):11-25
30. Zavascki AP, Goldani LZ, Li J, Nation RL (2007) Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60(6):1206-1215
31. Falagas ME, Kasiakou SK (2006) Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 10(1):R27
32. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM (2011) Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 1(1):1-7
33. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez F, Barrero-Almodovar A, Garcia-Garmendia J, Bernabeu-Wittell M, Gallego-Lara S, Madrazo-Osuna J (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36(9):1111-1118
34. Kim J, Lee K-H, Yoo S, Pai H (2009) Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34(5):434-438
35. Kofteridis DP, Alexopoulou C, Valachis A, Maraki S, Dimopoulou D, Georgopoulos D, Samonis G (2010) Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilator-associated pneumonia: a matched case-control study. Clin Infect Dis 51(11):1238-1244
36. Linden PK, Kusne S, Coley K, Fontes P, Kramer DJ, Paterson D (2003) Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa. Clin Infect Dis 37(11):e154-e160
37. Linden PK, Paterson DL (2006) Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 43(Supplement 2):S89-S94
38. Honoré PM, Jacobs R, Joannes-Boyau O, Lochy S, Boer W, De Waele E, Van Gorp V, De Regt J, Collin V, Spapen HD (2014) Continuous renal replacement therapy-related strategies to avoid colistin toxicity: a clinically orientated review. Blood Purif 37(4):291-295
39. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A (2005) Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 26(6):504-507
40. Katz R (1963) Renal and possibly hepatic toxicity from coly-mycin. Report of a case. Med Ann Dist Columbia 32:408
41. Ozkan G, Ulusoy S, Orem A, Alkanat M, Mungan S, Yulug E, Yucesan FB (2013) How does colistin-induced nephropathy develop and can it be treated? Antimicrob Agents Chemother 57(8):3463-3469
42. Ko H, Jeon M, Choo E, Lee E, Kim T, Jun J-B, Gil H-W (2010) Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 117(3):c284-c288
43. Rattanaumpawan P, Ungprasert P, Thamlikitkul V (2011) Risk factors for colistin-associated nephrotoxicity. J Infect 62(2):187-190
44. Kwon J-A, Lee JE, Huh W, Peck KR, Kim Y-G, Kim DJ, Oh HY (2010) Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 35(5):473-477
45. Doshi NM, Mount KL, Murphy CV (2011) Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacother J Human Pharmacol Drug Ther 31(12):1257-1264
46. Kift EV, Maartens G, Bamford C (2014) Systematic review of the evidence for rational dosing of colistin. SAMJ: South African Med J 104(3):183-186
47. Garonzik S, Li J, Thamlikitkul V, Paterson D, Shoham S, Jacob J, Silveira F, Forrest A, Nation R (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55(7):3284-3294
48. Shavit L, Manilov R, Wiener-Well Y, Algur N, Slotki I (2013) Urinary neutrophil gelatinase-associated lipocalin for early detection of acute kidney injury in geriatric patients with urinary tract infection treated by colistin. Clin Nephrol 80(6):405-416
49. Han WK, Bonventre JV (2004) Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 10(6):476-482
50. Ghlissi Z, Hakim A, Mnif H, Ayadi FM, Zeghal K, Rebai T, Sahnoun Z (2013) Evaluation of colistin nephrotoxicity administered at different doses in the rat model. Ren Fail 35(8):1130-1135
51. Soni SS, Ronco C, Katz N, Cruz DN (2009) Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 28(3):165-174
52. Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, Dragan Y, Ferguson D, Fikes J (2014) Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. Toxicol Sci 137(2):278-291
53. http://www.irct.ir/searchresult.php?keyword=colistin&id=14693&number=5&field=g&prt=2&total=2&m=1 (2014) Zahra Sahraei. Accessed 23 Sept 2014
54. Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, Oguzulgen IK, Sindel S (2011) Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med 37(1):141-146
55. Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Melatonin attenuates colistin-induced nephrotoxicity in rats. Antimicrob Agents Chemother 55(9):4044-4049
56. Yousef JM, Chen G, Hill PA, Nation RL, Li J (2011) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemotherapy:dkr483
57. Ghlissi Z, Hakim A, Sila A, Mnif H, Zeghal K, Rebai T, Bougatef A, Sahnoun Z (2014) Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Pharmacol 37(3):960-966